Latest Headlines
-
Orange Biomed To Present Breakthrough Microfluidic Test For Lab-Accurate HbA1c In Minutes At Adlm 2025
6/26/2025
Orange Biomed—the inventor of the world’s first pocket-sized, microfluidic-based A1C analysis device, dedicated to improving access and accuracy in chronic condition care—has been selected to present a poster at the ADLM 2025 Clinical Lab Expo.
-
Major Investment From Genome Canada To Help Advance ClarityDX Prostate Adoption Across Canada
6/26/2025
Nanostics Inc., a precision health company developing diagnostic tests with its ClarityDX® platform technology, announced today significant financial support from Genome Canada and Genome Alberta through the Canadian Biotechnology Innovation and Commercialization Initiative (CBIC) to accelerate the integration of ClarityDX Prostate into the standard of care for prostate cancer screening across Canada.
-
Sysmex Corporation Receives Health Canada License For The CN-3000™ & CN-6000™ Automated Blood Coagulation Analyzers
6/25/2025
Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, announces that Sysmex has received Health Canada license for the automated blood coagulation analyzers CN Series:
-
Leica Biosystems Unveils Next-Gen Pathology Portfolio At ECDP 2025
6/25/2025
In a significant stride toward transforming the future of cancer diagnostics and research, Leica Biosystems proudly showcases its latest digital pathology portfolio solutions at booth #50 during the European Congress on Digital Pathology.
-
SmartVascular Dx™ Test: Enhancing Vascular Care In The Midwest
6/25/2025
MorningStar Laboratories, LLC., (“MSL” or “the Company”), is a leading developer of precision diagnostic tests that address unmet clinical needs, is proud to announce its expansion in the Midwest with the introduction of the SmartVascular Dx™ test (formally known as the PULS™ Cardiac Test), a groundbreaking tool designed to improve vascular health outcomes.
-
PathPresenter Receives FDA 510(k) Clearance For Digital Pathology Clinical Viewer
6/24/2025
PathPresenter a leading Image Management System and workflow platform for digital pathology, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the PathPresenter Clinical Viewer for the purpose of primary diagnosis.
-
Axim Biotechnologies Files Pre-Submission With FDA For CLIA Waiver Pathway On Lactoferrin Point-Of-Care Diagnostic Test
6/24/2025
Axim Biotechnologies, Inc. a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration (FDA) as the first formal step in seeking a Clinical Laboratory Improvement Amendments (CLIA) Waiver for its rapid, point-of-care Lactoferrin diagnostic test (TearScan Lf).
-
Genesis Reference Laboratories Launches Advanced PCR Measles Test To Enhance Early Detection And Outbreak Prevention
6/24/2025
Genesis Reference Laboratories, a leader in diagnostic testing, is proud to announce the launch of its new Polymerase Chain Reaction (PCR) Measles Test, a highly sensitive and rapid method for detecting the measles virus.
-
Galatea Bio And Fabric Genomics Partner To Deliver Comprehensive Genetic Testing For Common Diseases
6/23/2025
Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.
-
Quanterix Expands Reach With IVD And Large Reference Labs
6/23/2025
Quanterix Corporation a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that the HD-X Simoa Immunoassay Analyzer has received Class 1 Medical Device registration by the Ministry of Food and Drug Safety (MFDS) in South Korea through its regional distribution partner, HS Biosystems.